Vaccines & Vaccination

Liana Monica Deac Graduated Medicine from University of medicine and Pharmacy, Cluj-Napoca, Romania. General Practitioner from 1979 to 1982 Clujana Hospital. She is a specialist for Infect. Diseases & Clinical Laboratory from 1987 to present. She is also a Senior Epidemiologist through 1993 to present. MD, PhD, First Degree Researcher and Scientist from 1996 to present. She is serving as a university Professor at Babes Bolyai University from 2004 to present.

Epidemiology

Maria Lazaro is a Pharmacist from Complutense University of Madrid. He/She(according to the author’s gender) holds advanced master’s in Biotechnology and Pharmaceutical Management works for Seppic in Human Biologicals department (adjuvants for vaccines and excipients for injectables ) since 2012.

animal health, vaccine manufacture, vaccine development

Marek Malecki MD PhD is President of the Phoenix Foundation, San Francisco, CA, USA, Principal Investigator at the National Institutes of Health, Bethesda, MD, USA, and Visiting Professor at the University of Wisconsin. He earned the MD degree at the Medical Academy, Poznan followed by Residency/Fellowships in Molecular Medicine in Rigshospitalet, Copenhagen, Cancer Center, Vienna, and Cancer Center, Warsaw. He earned the PhD degree at the Polish Academy of Sciences, Warsaw followed by the postdoctoral fellowships in molecular biology at the Austrian Academy of Sciences, Salzburg, ETH, Zurich, Utrecht University, Utrecht, Cancer Center, Amsterdam, Biozentrum, Basel. Over the last 20 years, he held faculty positions in Oncology and Molecular Medicine at the leading teaching hospitals and medical universities in the USA including the UW, UCSD, and SDSU. There, he acquired solid experience in streamlining advances in genomics and proteomics into novel strategies of therapy, as well as in teaching medical students, residents, and fellows. During his career, he served as the president and CEO of the Phoenix Biomolecular and Foundation for Molecular Medicine. Since 1988 his research, as the Principal Investigator, was continuously funded by the grants from the National Science Foundation and the National Institutes of Health. He is the first or senior author on the peer-reviewed publications in the high impact journals, which are indexed on the PubMed. He is the inventor of the gene therapies, therapeutic vaccines, and regeneration of tissues, which are published at the USPTO and WIPO. He was elected to serve as the Editor in Chief in peer-reviewed, open-access journals in Science, Technology, and Medicine, as well as Editorial Board Member and Reviewer at many others.

Vaccines for virus infected patients.

Dennis Christensen is a Head of Vaccine Delivery and Formulation Research Section at Statens Serum Institut. He is responsible for the vaccine formulation research. Designing novel vaccine delivery systems based on liposomes and research within mechanistic understanding of the vaccine delivery systems with relation to immunological efficacy.

The use of liposomes and emulsions as delivery systems for immunostimulators and vaccine antigens. • Examination of how physicochemical properties of liposomes, emulsions and antigens as well as different delivery and delivery routing routes may affect the immunological result.

Dr. Frédéric Deschamps is a medical doctor since 1990 and he has completed his PhD of toxicology in 1993 at the University of Lille, France. He is the director of the Department of Occupational Health of the Medicine Faculty of Reims, France. He has published more than 40 papers in medical journals about occupational health and diseases.

Flu vaccines

Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). His researches have been concerned with the characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.

Clinical and laboratory applied, Virology basic and diagnostic, Viral Oncology, Immunology clinical practice,Vaccines.

Dr. Masoud H Manjili is an Associate Professor of Immunology at the Department of Microbiology Immunology Virginia Commonwealth University School of Medicine and Member of Massey Cancer Center Richmond VA. He conducted his postdoctoral fellowship at Roswell Park Cancer Institute Buffalo NY 1999-2003. He has received a PhD in Immunology from The University of Sydney Australia 1993-1996. He has received a DVM from The University of Tehran Iran 1983-1990. He is serving as a Managing Editor of Frontiers in Bioscience.

Immunotherapy of tumor dormancy, Re-programming tumor-immune crosstalk to overcome tumor escape, Prognostic biomarkers for cancer, The adaptation model of immunity

Brian Abel received his Ph.D. in 2006 at the ETH, Zurich, and thereafter conducted a postdoctoral fellowship at SATVI, University of Cape Town, where he oversaw the immunological assessment of a novel TB vaccine in clinical trials and contributed to TB biomarker discovery. Brian completed an MBA at Tel Aviv University and ISB, Hyderabad, to facilitate a transition from academia into translational roles in biomedical science. Brian joined SIgN in 2012 to manage the Immunomonitoring Platform, conducting business development, project management and supporting finalization of agreements with industry partners, as well as acquiring regulatory approval for clinical research. He is also actively involved in Platform technology development in order to keep it up to date with the latest advances in the field of Immunomonitoring. In August 2016, Brian became the Head of the Immunogenomics Core to support and drive genomic activities for SIgN's researchers and facilitate collaborations with industry partners.

He is actively involved in Platform technology development in order to keep it up to date with the latest advances in the field of Immunomonitoring.